Navigation Links
BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008

SAN MATEO, Calif., Sept. 4 /PRNewswire-FirstCall/ -- BioForm Medical, Inc. (Nasdaq: BFRM) today announced its financial results for the fourth quarter and full fiscal year ended June 30, 2008. Net sales were $16.7 million for the quarter ended June 30, 2008 as compared to $15.4 million for the quarter ended June 30, 2007, an increase of $1.3 million or 8.4%. The net loss was $20.0 million for the quarter ended June 30, 2008 as compared to a net loss of $4.9 million for the quarter ended June 30, 2007. Net sales were $67.5 million for fiscal year 2008 as compared to $47.4 million for fiscal year 2007, an increase of $20.1 million or 42.4%. The net loss was $29.5 million for the fiscal year 2008 as compared to $13.6 million for fiscal year 2007. The $20.0 million net loss in the fourth quarter and the $29.5 million net loss for fiscal year 2008 each included an $11.2 million charge for acquired in-process research and development arising from the purchase of substantially all assets of Advanced Cosmetic Intervention, Inc. (ACI) in April 2008.

Operating Results:

Domestic sales were $13.2 million for the quarter ended June 30, 2008 as compared to $12.7 million for the quarter ended June 30, 2007, an increase of $0.5 million or 3.9%. International sales were $3.5 million for the quarter ended June 30, 2008, as compared to $2.6 million for the quarter ended June 30, 2007, an increase of $0.9 million or 34.6%. Gross profit was $14.4 million for the quarter ended June 30, 2008 as compared to $12.4 million for the quarter ended June 30, 2007, an increase of $2.0 million, or 16.1%. As a percentage of sales, gross profit for the quarter ended June 30, 2008 was 86.3% as compared to 81.1% for the quarter ended June 30, 2007. The increase in gross profit margin for the quarter ended June 30, 2008 was primarily due to a variation of production volume and overhead expense incurred, and lower royalty license expense.

Operating expenses were $34.7 million in the quarter ended June 30, 2008 as compared to $17.5 million in the quarter ended June 30, 2007. The increase in operating expenses was primarily attributable to the expensing of in-process research and development arising from the acquisition of assets from ACI, an increase in sales and marketing costs as a result of the expansion of the Company's sales forces in the United States and Europe in early fiscal 2008, expansion of the Company's clinical education programs, and additional higher employee-related expenses.

Net loss per share applicable to common stockholders decreased to $0.43 for the quarter ended June 30, 2008 as compared to $1.20 for the quarter ended June 30, 2007, due primarily to the increase in the shares outstanding as a result of the sale of 11.5 million shares of common stock in the Company's November 2007 initial public offering and the conversion of 30.4 million shares of preferred stock into common stock concurrent with this public offering.

Fiscal Year 2009 Guidance:

BioForm Medical is providing the following financial guidance for the full fiscal year ended June 30, 2009:

-- Revenues are expected to be approximately $74 to $78 million.

-- Gross profit is expected to average approximately 81% to 83% as a

percentage of sales on an annual basis, with some possible fluctuation

outside of this range on a quarterly basis.

-- Operating expenses are expected to be approximately $84 to $86 million.

-- Net loss is expected to be approximately $20 to $23 million.

Product Pipeline Update:

BioForm Medical is providing the following update on its product pipeline:

-- RADIESSE(R) Dermal Filler Next-Generation Products: The Company has a

number of ongoing programs evaluating new forms, applications and

indications of its patent protected RADIESSE dermal filler technology.

The first new commercial product derived from these efforts is expected

to be a form of RADIESSE dermal filler with Lidocaine which may improve

comfort for patients and flow characteristics for physicians, and is

expected to be launched in the United States and Europe in calendar

year 2009.

-- RADIESSE(R) Dermal Filler Post-Market Studies: The Company has

completed and submitted to FDA the results of two post-approval studies

for RADIESSE filler -- a three-year post-approval open-label follow-up

to the pivotal nasolabial fold study to evaluate the long-term safety

and duration of effect with RADIESSE filler, and a study to assess the

safety of RADIESSE dermal filler in nasolabial folds in persons of

color. In the three-year study in nasolabial folds, more than 30% of

treated nasolabial folds were rated by the treating investigator as

improved in patients who were two to three years from their last

injection. No long-term product related adverse events or

delayed-onset adverse events were reported in the study. In the

persons of color study, observed adverse events were typical of dermal

fillers such as redness, swelling, and bruising, and the study found

that RADIESSE dermal filler is safe for use in persons of color. These

studies were conducted pursuant to the requirements of the FDA

associated with the approval for RADIESSE dermal filler for facial

folds and wrinkles.

-- POLIDOCANOL: As announced in a separate press release today, positive

results from the Phase III clinical trial of Polidocanol (European

trade name Aethoxysklerol(R)), a sclerotherapy product for the

treatment of spider and reticular veins, have been submitted to FDA as

part of the New Drug Application (NDA) process. In addition to this

clinical report, BioForm Medical's partner, Kreussler, is completing

manufacturing documentation for a newly expanded manufacturing

facility. The final manufacturing documentation is expected to be

completed and submitted to FDA before the end of calendar year 2008,

consistent with BioForm Medical's previously reported expected timeline

for completion of the NDA submission.

-- RELAXED EXPRESSIONS(TM): As previously announced on April 30, 2008,

BioForm Medical acquired from ACI a minimally invasive bi-polar

radiofrequency 510(k) medical device (renamed "Relaxed

Expressions(TM)") cleared to selectively reduce nerve function. The

Company has recently received an additional 510(k) clearance for a new

treatment profile software upgrade designed to improve outcomes of

procedures with the device. The Company has filed an Investigational

Device Exemption (IDE) with the FDA to conduct clinical studies

specifically intended to support an FDA application seeking clearance

to market this product for the treatment of frown lines. The Company

expects to also seek a CE Mark and certain other international

registrations of the Relaxed Expressions device for aesthetics


-- BIOGLUE Aesthetic(TM) Medical Adhesive: The Company and its partner,

CryoLife, Inc. announced in June 2008 the receipt of a CE Mark for

BioGlue Aesthetic(TM) Medical Adhesive for browplasties in Europe.

Pre-launch activities continue on a limited basis with early users, to

help the Company in its evaluation and development program to identify

and optimize uses of BioGlue Aesthetic adhesive. In the United States,

BioForm has completed a 30-patient feasibility study for the use of

BioGlue Aesthetic adhesive conducted under a U.S. IDE which

demonstrated raised brow position in 89% of patients at 6 months.

BioForm is working with its clinical advisors and FDA to determine the

best design for a pivotal study of BioGlue Aesthetic adhesive to

support U.S. approval.

"We are pleased to report sales performance for the quarter and fiscal year ended June 30, 2008 in line with the guidance we provided in our third quarter fiscal 2008 conference call and earnings release. Our guidance for fiscal year 2009 reflects an expectation that the current dermal filler market softness will persist for two more quarters, with only modest recovery starting thereafter," commented Steve Basta, Chief Executive Officer of BioForm Medical, Inc. "In fiscal 2009, we are focused on training and education to drive clinical confidence among RADIESSE dermal filler users, expanding the RADIESSE filler user base through new account conversions, and developing our future products, which we believe will contribute to accelerating revenue growth in fiscal 2010 and beyond."

Conference Call:

BioForm Medical will hold a conference call today at 2:00 pm Pacific Time (5:00 p.m. Eastern Time) to discuss the financial results and guidance. The conference call will be webcast live on the Investor Relations section of BioForm Medical's website at The conference call may be accessed by dialing 888-287-5530 for callers in the U.S. and 719-785-1786 for international callers. Please notify the operator that you would like to join "BioForm Medical's Fourth Quarter & Fiscal 2008 Earnings Call" and provide the participant code "2257477", if prompted.

About BioForm Medical, Inc.:

BioForm Medical, Inc. is a medical aesthetics company headquartered in San Mateo, California, developing products that enhance aesthetic procedures performed in dermatology and plastic surgery practices. BioForm Medical's lead product is Radiesse(R) dermal filler, a long-lasting filler for use in facial aesthetics. BioForm Medical is developing several future aesthetics products, including a radiofrequency treatment to reduce nerve function in the forehead, a sclerotherapy treatment for spider veins, and a surgical adhesive for brow lifts. For more information about BioForm, please visit

Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Specifically, statements concerning the introduction of new RADIESSE products or the timing thereof, the timing of completing a Polidocanol NDA submission to FDA, the timing of an FDA application or receipt of FDA clearance, or international regulatory clearances, to market Relaxed Expressions for the treatment of frown lines or other aesthetic indications, the ability of the Company to optimize uses of BioGlue Aesthetic adhesive in Europe or to advance a clinical program for regulatory clearance of the product in the United States, the commercial success of future product introductions, and financial guidance for fiscal year 2009 are forward-looking statements within the meaning of the Safe Harbor. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties, which may cause BioForm Medical's actual results to differ materially from the statements contained herein. BioForm Medical's fiscal 2008 financial results, as discussed in this release, are preliminary and unaudited, and subject to adjustment. Further information on potential risk factors that could affect BioForm Medical's business and its financial results are detailed in its latest Form 10-Q as filed with the Securities and Exchange Commission on May 9, 2008. Undue reliance should not be placed on forward-looking statements, especially guidance on future financial performance, which speaks only as of the date they are made. BioForm Medical undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.


Adam Gridley


Vice President, Corporate Development

BioForm Medical, Inc.



(in thousands, except per share data)

Three months ended Twelve months ended

June 30, June 30,

2008 2007 2008 2007

Net U.S. sales $13,220 $12,726 $54,393 $39,215

Net International sales 3,492 2,624 13,090 8,199

Net sales 16,712 15,350 67,483 47,414

Cost of sales 2,289 2,901 11,393 8,769

Gross profit 14,423 12,449 56,090 38,645

Operating expenses:

Sales and marketing 17,702 11,783 56,912 38,186

Research and development 2,690 3,763 9,313 7,756

Acquired in-process research

and development 11,230 - 11,230 -

General and administrative 3,090 1,957 9,882 6,990

Total operating expenses 34,712 17,503 87,337 52,932

Other income (expense), net

Interest income, net 412 199 1,902 842

Other income (expense), net (51) 6 110 68

Loss before income taxes (19,928) (4,849) (29,235) (13,377)

Provision for income taxes 80 72 290 195

Net loss $(20,008) $(4,921) $(29,525) $(13,572)

Net loss per common share, basic

and diluted $(0.43) $(1.20) $(0.94) $(3.54)

Weighted-average number of

common shares used in per

share calculation, basic

and diluted 46,257 4,104 31,276 3,839



(in thousands)

Years Ended June 30,

2008 2007


Current assets:

Cash and cash equivalents $59,204 $17,610

Accounts receivable, net of allowance for

doubtful accounts of $836 at June 30, 2008

and $428 at June 30, 2007, 10,989 7,725

Inventories 8,167 4,864

Prepaid royalties 929 -

Prepaid other 1,603 1,194

Other current assets 805 262

Total current assets 81,697 31,655

Property and equipment, net 9,037 5,741

Prepaid royalties 3,288 -

Other assets 548 103

Total assets $94,570 $37,499

Liabilities and stockholders' equity

Current liabilities:

Accounts payable $3,533 $3,754

Deferred revenues 454 446

Accrued royalty expenses 280 869

Accrued liabilities 8,066 6,686

Capital lease obligations, current portion 34 20

Total current liabilities 12,367 11,775

Capital lease obligations, long-term portion 60 36

Total liabilities 12,427 11,811

Total stockholders' equity 82,143 25,688

Total liabilities and stockholders' equity $94,570 $37,499

SOURCE BioForm Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioForm Medical to Present at the 2008 JPMorgan Healthcare Conference on January 7, 2008
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. QMed, Inc. Reports July Medicare SNP Enrollments
4. Phlo Affiliate Reports Expanded Coverage to Oregon Border
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Carrington Reports Second Quarter 2007 Results
8. Avitar Reports Third Quarter Financial Results for Fiscal 2007
9. Response Genetics Reports Second Quarter 2007 Financial Results
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Transgenomic, Inc. Reports Second Quarter 2007 Results
Post Your Comments:
(Date:11/24/2015)... 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will ... New York on Wednesday, December 2 at 9:30 a.m. ... and CEO, will provide a corporate overview. th ... at 1:00 p.m. ET/10:00 a.m. PT . Jim Mazzola ... a corporate overview. --> th Annual Oppenheimer Healthcare ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... event of the year and one of the premier annual events for pharmaceutical ... ran from 8–11 November 2015, where ISPE hosted the largest number of attendees ...
(Date:11/24/2015)... November 24, 2015 --> ... research report "Oligonucleotide Synthesis Market by Product & Services ... Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, ... MarketsandMarkets, the market is expected to reach USD 1,918.6 ... at a CAGR of 10.1% during the forecast period. ...
(Date:11/24/2015)... 2015 SHPG ) announced today that ... Jaffray 27 th Annual Healthcare Conference in New ... 8:30 a.m. EST (1:30 p.m. GMT). --> SHPG ) ... participate in the Piper Jaffray 27 th Annual Healthcare Conference ... December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ...
Breaking Biology Technology:
(Date:11/10/2015)... Nov. 10, 2015  In this report, ... basis of product, type, application, disease indication, ... this report are consumables, services, software. The ... safety biomarkers, efficacy biomarkers, and validation biomarkers. ... are diagnostics development, drug discovery and development, ...
(Date:11/2/2015)... 2, 2015  SRI International has been awarded a ... development services to the National Cancer Institute (NCI) PREVENT ... scientific expertise, modern testing and support facilities, and analytical ... and toxicology studies to evaluate potential cancer prevention drugs. ... PREVENT Cancer Drug Development Program is an NCI-supported pipeline ...
(Date:10/29/2015)... , Oct. 29, 2015  Connected health pioneer, ... the explosion of technology-enabled health and wellness, and the ... book, The Internet of Healthy Things ... or smartphones even existed, Dr. Kvedar, vice president, Connected ... health care delivery, moving care from the hospital or ...
Breaking Biology News(10 mins):